J
Jan Molinsky
Researcher at First Faculty of Medicine, Charles University in Prague
Publications - 18
Citations - 330
Jan Molinsky is an academic researcher from First Faculty of Medicine, Charles University in Prague. The author has contributed to research in topics: Mantle cell lymphoma & Apoptosis. The author has an hindex of 8, co-authored 18 publications receiving 286 citations. Previous affiliations of Jan Molinsky include Charles University in Prague.
Papers
More filters
Journal ArticleDOI
Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
Tabea Erdmann,Pavel Klener,Pavel Klener,James T. Lynch,Michael Grau,Petra Vockova,Petra Vockova,Jan Molinsky,Jan Molinsky,Diana Tuskova,Diana Tuskova,Kevin Hudson,Urszula M. Polanska,Michael Grondine,Michele Mayo,Beiying Dai,Matthias Pfeifer,Kristian Erdmann,Daniela Schwammbach,Myroslav Zapukhlyak,Annette M. Staiger,Annette M. Staiger,German Ott,Wolfgang E. Berdel,Barry R. Davies,Francisco Cruzalegui,Marek Trneny,Marek Trneny,Peter Lenz,Simon T. Barry,Georg Lenz +30 more
TL;DR: The data suggest that patients should be stratified according to their oncogenic dependencies when treated with PI3K and AKT inhibitors when treating DLBCLs irrespective of their molecular subtype.
Journal ArticleDOI
Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma
Magdalena Klanova,Magdalena Klanova,Ladislav Andera,Jan Brazina,Jan Svadlenka,Simona Benesova,Jan Soukup,Dana Prukova,Dana Vejmelkova,Radek Jaksa,Karel Helman,Petra Vockova,Petra Vockova,Lucie Lateckova,Lucie Lateckova,Jan Molinsky,Jan Molinsky,Bokang Maswabi,Mahmudul Alam,Roman Kodet,Robert Pytlik,Marek Trneny,Pavel Klener,Pavel Klener +23 more
TL;DR: DLBCL can be divided into BCL2-dependent and MCL1-dependent subgroups with a less pronounced role left for BCL-XL, and concurrent inhibition of BCL1 with ABT-199 and HHT induced significant synthetic lethality in most B CL2-expressing DLBCL cell lines.
Journal ArticleDOI
B-cell receptor–driven MALT1 activity regulates MYC signaling in mantle cell lymphoma
Beiying Dai,Michael Grau,Mélanie Juilland,Pavel Klener,Pavel Klener,Elisabeth Höring,Elisabeth Höring,Jan Molinsky,Jan Molinsky,Gisela Schimmack,Sietse M. Aukema,Eva Hoster,Niklas Vogt,Annette M. Staiger,Annette M. Staiger,Tabea Erdmann,Wendan Xu,Kristian Erdmann,Nicole Dzyuba,Hannelore Madle,Wolfgang E. Berdel,Marek Trneny,Martin Dreyling,Korinna Jöhrens,Peter Lenz,Andreas Rosenwald,Reiner Siebert,Reiner Siebert,Alexandar Tzankov,Wolfram Klapper,Ioannis Anagnostopoulos,Daniel Krappmann,German Ott,Margot Thome,Georg Lenz +34 more
TL;DR: It is shown that a subset of MCLs is addicted to MALT1, as its inhibition by either RNA or pharmacologic interference induced cytotoxicity both in vitro and in vivo.
Journal ArticleDOI
Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
Magdalena Klanova,Lucie Lorkova,Ondrej Vit,Bokang Maswabi,Jan Molinsky,Jana Pospisilova,Petra Vockova,Cory Mavis,Lucie Lateckova,Vojtech Kulvait,Dana Vejmelkova,Radek Jaksa,Francisco Hernandez,Marek Trneny,Martin Vokurka,Jiri Petrak,Pavel Klener +16 more
TL;DR: Acquired resistance of MCL cells to araC is associated with downregulation of DCK, enzyme of the nucleotide salvage pathway responsible for the first phosphorylation (=activation) of most nucleoside analogs used in anti-cancer therapy.
Journal ArticleDOI
Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research.
Magdalena Klanova,Tomáš Soukup,Radek Jaksa,Jan Molinsky,Lucie Lateckova,Bokang Maswabi,Dana Prukova,Jana Brezinova,Kyra Michalova,Petra Vockova,Francisco J. Hernandez-Ilizaliturri,Vojtech Kulvait,Jan Zivny,Martin Vokurka,Emanuel Necas,Marek Trneny,Pavel Klener +16 more
TL;DR: It is demonstrated that engrafted MCL cells displayed complex changes of GEP, protein expression, and sensitivity to cytotoxic agents when compared with controls, and could be used to test the therapeutic activity of systemic chemotherapy, monoclonal antibodies, or angiogenesis inhibitors.